UPDATE: Citigroup Reiterates Neutral Rating, Raises PT on Allscripts Healthcare Solutions

Loading...
Loading...
In a report published Wednesday, Citigroup reiterated its Neutral rating on Allscripts Healthcare Solutions
MDRX
, and slightly raised its price target from $10.50 to $11.00. Citigroup noted, “We believe Allscripts faces significant challenges on the product development and sales execution fronts, but many of these challenges are priced into the stock. We are modestly raising our 2012 and 2013 EPS estimates on the company's recent aggressive repurchase of shares. We are not yet ready to get more positive on the shares, but could be in a position to do so if we believe the company can fix its operational issues and restore faith to its customer base.” Allscripts Healthcare Solutions closed Tuesday at $9.79.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...